ABVX — Abivax SA Share News
0.000.00%
Last trade - 00:00Brief: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy
Brief: Abivax Expects To Be Able To Finance Its Operating Cash Flow Requirements Into Q4 2025
Brief: Abivax Announces Abtect Phase 3 Trial Achieves Key Enrollment Milestone
Brief: Abivax Provides Operational And Key Program Update
Brief: Abivax Sees Sufficient Funds To Finance Operations Into Q4 2025
Brief: Abivax Provides 2024 Strategic Outlook, Lays Out Key Milestones Over Next 12 Months
Brief: Abivax: Closing of IPO on Nasdaq Global Market
France's Abivax plunges after low-end US IPO pricing
Brief: Abivax Announces Trading Resumption On Euronext Paris
Brief: Abivax Announces Pricing For Nasdaq IPO
Brief: Abivax Temporarily Halts Trading On Euronext Paris
Brief: Abivax says IPO offering price between $11.60 and $13.00 per ADS
Brief: Abivax SA Offering An Aggregate Of 18.7 Million Ordinary Shares In A Global Offering - SEC Filing
Brief: Abivax SA Files Initial Public Offering Of Adss In The United States
Brief: Abivax Posts H1 Operating Loss Of EUR 37.3 Million
Brief: Abivax Provides Business And Operational Update
Brief: Abivax Secures Up To EUR 150 Mln From Two Structured Debt Financing Transactions
Brief: Abivax Announces Plans For Registered Public Offering In US
Brief: Abivax Postpones Publication Of Its 2023 Universal Registration Document